Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

HTG Molecular Diagnostics and PROOF Centre Partner to Commercialize COPD Prognostic Test

Published: Tuesday, November 27, 2012
Last Updated: Tuesday, November 27, 2012
Bookmark and Share
The license agreement provides HTG Molecular Diagnostics exclusive rights to commercialize PROOF Centre-developed gene expression blood tests for the prognosis of COPD patients who will experience frequent exacerbations.

HTG Molecular Diagnostics will develop the assay on its proprietary qNPA platform. The PROOF Centre -- a not-for-profit organization focused on developing blood tests for chronic organ disease -- will be involved in the clinical validation in Canada, and provide key opinion leader support for regulatory approval in North America.

Lung attacks are the leading cause of emergency room visits and hospitalizations among chronic disease sufferers, accounting for over $5.7 billion direct, and $6.7 billion indirect healthcare costs every year in Canada alone. According to the World Health Organization (WHO), an estimated 210 million people worldwide have COPD and three million deaths are attributed to the disease annually. WHO predicts COPD will become the third leading cause of death by 2030. A large portion of COPD-related mortality is due to lung attacks.

"The development of these blood tests has been driven by a huge unmet clinical and social need," says Dr. Bruce McManus, Director of the PROOF Centre. "This agreement with HTG Molecular Diagnostics will facilitate bringing these tests to market faster, providing physicians with tools to improve patient care and management and help alleviate suffering of patients with COPD."

Currently, physicians have limited capabilities to predict which COPD patients will suffer frequent lung attacks, episodes that result in hospitalization and a reduced quality of life. The ability to identify these patients earlier will enable physicians to intervene sooner and better tailor treatment for the individual patient to prevent future lung attacks.

TJ Johnson, CEO of HTG Molecular Diagnostics, states, "Delivery of an accurate, early predictor of frequent patient lung attacks, and providing the ability to personalize preventive care is of paramount importance to pulmonology practitioners and patients. This agreement is the first of many that HTG Molecular Diagnostics and PROOF Centre hope to have to bring medically valuable biomarker tests to the clinic."

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More Than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

HTG Molecular Diagnostics Licenses Breast Cancer Marker Patent Portfolio From Merck
Company has been granted a non-exclusive license to develop, manufacture, and commercialize breast cancer diagnostic tests under Merck's patent portfolio.
Wednesday, July 11, 2012
HTG Molecular Diagnostics Appoints Debra Gordon to Vice President, Chief Legal Counsel
Debra Gordon brings diverse legal experience as a business transactional and intellectual property attorney at leading U.S. and international law firms.
Tuesday, June 21, 2011
HTG Molecular Diagnostics Secures New Investor, SR One
Venture capital arm of GlaxoSmithKline joins second tranche of series D financing round.
Wednesday, June 15, 2011
Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
How a Genetic Locus Protects Adult Blood-Forming Stem Cells
Mammalian imprinted Gtl2 protects adult hematopoietic stem cells by restricting metabolic activity in the cells' mitochondria.
Genetic Basis of Fatal Flu Side Effect Discovered
A group of people with fatal H1N1 flu died after their viral infections triggered a deadly hyperinflammatory disorder in susceptible individuals with gene mutations linked to the overactive immune response, according to a recent study.
New Tech Vastly Improves CRISPR/Cas9 Accuracy
A new CRISPR/Cas9 technology developed by scientists at UMass Medical School is precise enough to surgically edit DNA at nearly any genomic location, while avoiding potentially harmful off-target changes typically seen in standard CRISPR gene editing techniques.
The MaxSignal Colistin ELISA Test Kit from Bioo Scientific
Kit can help prevent the antibiotic apocalypse by keeping last resort drugs out of the food supply.
"Good" Mozzie Virus Might Hold Key to Fighting Human Disease
Australian scientists have discovered a new virus carried by one of the country’s most common pest mosquitoes.
Non-Disease Proteins Kill Brain Cells
Scientists at the forefront of cutting-edge research into neurodegenerative diseases such as Alzheimer’s and Parkinson’s have shown that the mere presence of protein aggregates may be as important as their form and identity in inducing cell death in brain tissue.
Closing the Loop on an HIV Escape Mechanism
Research team finds that protein motions regulate virus infectivity.
New Class of RNA Tumor Suppressors Identified
Two short, “housekeeping” RNA molecules block cancer growth by binding to an important cancer-associated protein called KRAS. More than a quarter of all human cancers are missing these RNAs.
Potential Treatment for Life-Threatening Viral Infections Revealed
The findings point to new therapies for Dengue, West Nile and Ebola.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos